Infusion-transfusion therapy in treatment of acute massive surgical blood loss in cancer surgery: 615.273.52

Abstract

Summary. Background. Cancer surgery remains the backbone of treatment approaches in patients with locally advanced solid malignancies. Risk of acute massive blood loss (AMBL) remains the main complication of such large-scale cancer surgery. Objectives: assessment of AMBL tolerance in cancer patients. Patients/Methods. A single-center retrospective study from January 1999 to December 2018 included 4,236 patients who underwent radical surgery for malignant tumors of various localizations, whose course of surgery was complicated with AMBL. The AMBL criterion was the loss of ≥ 50% of the calculated circulating blood volume (СBVс) within 3 hours of the operation. The patients included in the study were divided into 4 groups depending on the volume of blood loss: from 51 to 100%, from 101 to 200%, from 201 to 300% and over 300% of СBVс. Results. Patients of the studied groups did not differ either in general parameters or in baseline somatic status. The qualitative and quantitative composition of infusion- transfusion therapy (ITT), intraoperative fluid balance, patients stay in the intensive care unit, and mortality were analyzed. Conclusions. Compliance with a specific ITT protocol during cancer surgery complicated by AMBL is the key to successful treat- ment and allows to reduce intraoperative mortality to 0.8% and hospital mortality to 6.45%. The method of intraoperative red cell salvage and autologus transfusion has demonstrated high efficiency.

References:

1. Feoktistov P.I., Karmanov I.E. Extreme blood loss in canser sur- gery: is it a verdict to the patient or a challenge to the staff? Klinicheskaya praktika. 2019;10(3):42–8. (In Russ.). DOI: 10.17816/ clinpract10342–48.

1. Cata J.P., Gottumukkala V. Blood loss and massive transfusion in patients undergoing major oncological surgery: what do we know? ISRN Anesthesiology. 2012;2012:918938. DOI: 10.5402/2012/918938.
2. Hasselgren K., Sandström P., Gasslander T., Björnsson B. Multi- visceral resection in patients with advanced abdominal tumors. Scand J Surg. 2016;105(3):147–52. DOI: 10.1177/1457496915622128.
3. Cata J.P., Gottumukkala V. Blood transfusion practices in cancer surgery. Indian J Anaesth. 2014;58(5):637–42. DOI: 10.4103/0019– 5049.144675.
4. Turan A., Yang D., Bonilla A. et al. Morbidity and mortality after massive transfusion in patients undergoing non-cardiac surgery. Can J Anesth. 2013;60(8):761–70. DOI: 10.1007/s12630–013–9937–3.
5. Pepe A., Meyer J., Zwissler B., Hubler O. How to manage a patient with massive intraoperative blood loss. In collection: Actual problems of anesthesiology and resuscitation (12th edition). Ed. E.V. Nedashkovsky. Arkhangelsk, 2007. 82–91. (In Russ.).
6. Charlson M, Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245– 
 DOI: 10.1016/0895–4356(94)90129–5. 

7. Mayhew D., Mendonca V., Murthy B.V.S. A review of ASA physi- 
cal status — historical perspectives and modern developments. 
Anaesthesia. 2019;74(3):373–9. DOI: 10.1111/anae.14569. 

8. DellaRocca G., Vetrugno L., Tripi G. еt al. Liberal or restricted fluid administration: are we ready for a proposal of a restricted intraoperative approach? BMC Anesthesiology. 2014;14:62. DOI: 
1186/1471–2253–14–62. 

9. Fernández-Hinojosa E., Murillo-Cabezas F., Puppo-Moreno A., 
Leal-Noval S.R. Treatment alternatives in massive hemorrhage. Med Intensiva. 2012;36(7):496–503. [Article in Spanish]. DOI: 10.1016/j.medine. 

10. Kozek-Langenecker S.A., Ahmed A.B., Afshari A. et al. Manage- ment of severe perioperative bleeding: guidelines from the Euro- pean Society of Anaesthesiology: First update 2016. Eur J Anaes- thesiol. 2017;34(6):332–95. DOI: 10.1097/ EJA.0000000000000630. 

11. Kirov M. Yu., Gorobets E.S., Bobovnik S.V. et al. Principles of peri- operative infusion therapy in adults. Anesteziologiya i reanima- tologiya. 2018;(6):82–103. (In Russ.). DOI: 10.17116/anesthesiol- ogy201806182. 

12. Orbegozo Cortés D., Gamarano Barros T., Njimi H., Vincent J.-L. Crystalloids versus colloids: exploring differences in fluid require- ments by systematic review and meta-regression. Anesth Analg. 2015;120(2):389–402. DOI: 10.1213/ANE.0000000000000564. 

13. Spahn D.R., Bouillon B., Cerny V. et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Critical Care. 2019;23(1):98. DOI: 10.1186/ s13054–019–2347–3. 

14. Joshi G.P. Intraoperative fluid management. UpToDate. Feb 03, 2020. Available at: www.uptodate.com. 

15. Patil V., Shetmahajan M. Massive transfusion and massive transfusion protocol. Indian J Anaesth. 2014;58(5):590–5. DOI: 10.4103/0019–5049.144662. 

16. Bolliger D., Görlinger K., Tanaka K.A. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemo- dilution. Anesthesiology. 2010;113(5):1205–19. DOI: 10.1097/ ALN.0b013e3181f22b5a. 

17. Rajasekhar A., Gowing R., Zarychanski R. et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med. 2011;39(6):1507–13. DOI: 10.1097/CCM.0b013e31820eb517. 

18. Schochl H., Nienaber U., Hofer G. et al. Goal-directed coagula- tion management of major trauma patients using thromboelas- tometry (ROTEM)-guided administration of fibrinogen concen- trate and protrombin complex concentrate. Crit Care. 2010;14(2): R55. DOI: 10.1186/cc8948. 

19. Shore-Lesserson L., Manspeizer H.E., Francis S., DePerio M. Intra- operative [Thrombelastograph® Analysis] (TEG [®]) reduces trans- fusion requirements. Anesth Analg. 1998;86(4S):101SCA. DOI: 10.1097/00000539–199804001–00101. 

20. Fredericks С., Kubasiak J.C, Mentzer C.J., Yon J.R. Massive trans- fusion: An update for the anesthesiologist. World J Anesthesiol. 2017;6(1):14–21. DOI: 10.5313/wja. 

21. Holcomb J.B., Tilley B.C., Baraniuk S. et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clini- cal trial. JAMA. 2015;313(5):471–82. DOI: 10.1001/jama.2015.12. 

22. I.,StensballeJ.,OliveriR.HowItreatpatientswith massive hemorrhage. Blood. 2014;124(20):3052–8. DOI: 10.1182/ blood-2014–05–575340. 

23. Borgman M.A., Spinella P.C., Perkins J.G. et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63(4):805–13. DOI: 10.1097/TA.0b013e3181271ba3.
24. Dirks J., Jorgensen H., Jensen C.H. et al. Blood product ratio in acute traumatic coagulopathy — effect on mortality in a Scandi- navian level 1 trauma centre. Scand J Trauma Resusc Emerg Med. 2012;18:65. DOI: 10.1186/1757–7241–18–65.
25. Johansson P.I., Stensballe J. Hemostatic resuscitation for mas- sive bleeding: the paradigm of plasma and platelets — a review of the current literature. Transfusion. 2010;50(3):701–10. DOI: 10.1111/j.1537–2995.2009.02458.x.
26. Almeida de J.P., Vincent J.-L., Galas F.R. et al. Transfusion require- ments in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology. 2015;122(1):29–38. DOI: 10.1097/ ALN.0000000000000511.
27. Rao S.V. Bleeding as a predictor of mortality risk. Rev Cardiovasc Med. 2006;7 Suppl 3:S12–8.
28. Sihler K.C., Napolitano L.M. Complications of massive transfusion. Chest. 2010;137(1):209–20. DOI: 10.1378/chest.09–0252.
29. Muirhead B., Weiss A.D.H. Massive hemorrhage and transfusion in the operating room. Can J Anaesth. 2017;64(9):962–78. DOI: 10.1007/s12630–017–0925-x.
30. Murphy G.J., Pike K., Rogers C.A. et al. Liberal or restrictive trans- fusion after cardiac surgery. N Engl J Med. 2015;372(11):997–1008. DOI: 10.1056/NEJMoa1403612.
31. Kind S. L., Spahn-Nett G.H, Emmert M. Y. et al. Is dilutional coagulopathy induced by different colloids reversible by replace- ment of fibrinogen and factor XIII concentrates? Anesth Analg. 2013;117(5):1063–71. DOI: 10.1213/ANE.0b013e3182a52876.
32. Moeller C., Fleischmann C., Thomas-Rueddel D. et al. How safe is gelatin? A systematic review and meta-analysis of gelatin- containing plasma expanders vs crystalloids and albumin. J Crit Care. 2016;35:75–83. DOI: 10.1016/j.jcrc.2016.04.011.
33. Feoktistov P.I., Gorobets Ye.S., Kostyak O.S. Experience in the treat- ment of extreme blood loss during oncological operations. Medi- cina kriticheskih sostoyanij. 2004;(6):30–5. (In Russ.). DOI: 10.17816/ clinpract10342–48.

1. Trudeau J.D., Waters T., Chipperfield K. Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? Can J Anaesth. 2012;59(11):1058–70. DOI: 10.1007/ s12630–012–9781-x.
2. Gakhar H., Bagouri M., Bommireddy R., Klezl Z. Role of intraope- rative red cell salvage and autologus transfusion in metastatic spine surgery: a pilot study and review of literature. Asian Spine J. 2013;7(3):167–72. DOI: 10.4184/asj.2013.7.3.167.
3. Ashworth A., Klein A.A. Cell salvage as part of a blood conserva- tion strategy in anaesthesia. Br J Anaesth. 2010;105(4):401–1. DOI: 1093/bja/aeq244.
4. Aning J., Dunn J., Daugherty M. et al. Towards bloodless cys- tectomy: a 10-year experience of intra-operative cell salvage during radical cystectomy. BJU Int. 2012;110(11 PtB):E608–13. DOI: 1111/j.1464–410X.2012.11338.x.
5. Raval J.S., Nelson J.B, Woldemichael E., Triulzi D.J. Intraoperative cell salvage in radical prostatectomy does not appear to increase long-term biochemical recurrence, metastases, or mortality. Trans- fusion. 2012;52(12):2590–93. DOI: 10.1111/j.1537–2995.2012.03682.x.
6. Mazurok V.A. Obvious and controversial issues of replacing acute massive blood loss. Hirurgicheskaya praktika. 2013;4:11–9. (In Russ.).
7. Chua T. C., Yan T. D., Saxena A., Morris D. L. Should the treat- ment of peritoneal carcinomatosis by cytoreductive sur- gery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900–7. DOI:10.1097/sla.0b013e3181a45d86.
8. Glance L.G., Dick A.W., Mukamel D.B. et al. Association between 
intraoperative blood transfusion and mortality and morbi- dity in patients undergoing noncardiac surgery. 2011;114(2):283–92. DOI: 10.1097/ALN.0b013e3182054d06. 

9. Keding V., Zacharowski K., BechsteinW.O. et al. Patient blood management improves outcome in oncologic surgery. World J Surg Oncol. 2018;16(1):159. DOI: 10.1186/s12957–018–1456–9. 

10. Martin A.N., Kerwin M.J., Turrentine F.E. et al. Blood transfu- sion is an independent predictor of morbidity and mortality after hepatectomy. J Surg Res. 2016;206(1):106–12. DOI: 10.1016/j. jss.2016.07.013. 

11. Zhang X.-P., Gao Y.-Z., Chen Z.-H. et al. In-hospital mortality after surgical resection in hepatocellular carcinoma patients with por- tal vein tumor thrombus. J Cancer. 2019;10(1):72–80. DOI: 10.7150/ 27102. 

12. Galstyan G.M., Polevodova O.A., Terekhova I.V. et al. The use of thromboelastography, thrombin generation test and clotting tests to evaluate the efficacy of hemostatic therapy with recombinant activated factor VII in hemophilia patients with inhibitor. Rossijskij zhurnal detskoj gematologii i onkologii. 2017;4(4):33–8. (In Russ.). DOI: 10.17650/2311–1267–2017–4–4–33–38. 

13. Trekova N.A., Guskov D.A., Goncharova A.V., Akselrod B.A. The efficacy of recombinant activated factor VII (coagil VII) for treatment haemorrhage and haemostasis disorders during tho- racic aorta operations. Vestnik anesteziologii i reanimatologii. 2019;16(3):25–31. (In Russ.). DOI: 10.21292/2078–5658–2019–16– 3–25–31.
14. Hauser C.J., Boffard K., Dutton R. et al. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010;69(3):489–500. DOI: 10.1097/TA.0b013e3181edf36e.
15. Segal S., Shemesh I.Y., Blumenthal R. et al. Treatment of obstet- ric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet. 2003;268(4):266–7. DOI: 10.1007/s00404– 002–0409–1.
16. Nekhaev I.V., Prikhodchenko A.O. Variants of control and correc- tion of hemostasis in oncosurgical patients. Moscow: ABV-press, 2019. 136 pр. (In Russ.).
17. Nekhaev I.V., Prikhodchenko A.O., Vyatkin P.V. et al. Periopera- tive coagulopathies in oncosurgery. Prothrombin complex con- centrate. Tromboz, gemostaz i reologiya. 2016;(1):39–50. (In Russ.).
18. Nekhaev I.V., Prikhodchenko A.O., Lomidze S.V., Sytov A.V. Epta- cog alpha. Application experience. Tromboz, gemostaz i reologiya. 2017;(4):63–9. (In Russ.). DOI: 10.25555/THR.2017.4.0812